Therapeutic applications of TRAIL receptor agonists in cancer and beyond
- 5 September 2015
- journal article
- review article
- Published by Elsevier BV in Pharmacology & Therapeutics
- Vol. 155, 117-131
- https://doi.org/10.1016/j.pharmthera.2015.09.001
Abstract
No abstract availableKeywords
Funding Information
- Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
- Brazilian Research Council (CNPq)
- National Institutes of Health (CA109446)
- U.S. Department of Veterans Affairs Merit Review Program
This publication has 288 references indexed in Scilit:
- Cell Death in the Maintenance and Abrogation of Tolerance: The Five Ws of Dying CellsImmunity, 2011
- Interleukin-2 rescues helpless effector CD8+ T cells by diminishing the susceptibility to TRAIL mediated deathImmunology Letters, 2011
- Association of tumor necrosis factor-related apoptosis-inducing ligand with total and cardiovascular mortality in older adultsAtherosclerosis, 2011
- Statins reduce endothelial cell apoptosis via inhibition of TRAIL expression on activated CD4 T cells in acute coronary syndromeAtherosclerosis, 2010
- Phosphorylation-Driven Assembly of the RIP1-RIP3 Complex Regulates Programmed Necrosis and Virus-Induced InflammationCell, 2009
- Receptor Interacting Protein Kinase-3 Determines Cellular Necrotic Response to TNF-αCell, 2009
- Induction of Immunological Tolerance by Apoptotic Cells Requires Caspase-Dependent Oxidation of High-Mobility Group Box-1 ProteinImmunity, 2008
- Safety and antitumor activity of recombinant soluble Apo2 ligandJCI Insight, 1999
- Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF.JCI Insight, 1998
- Molecular cloning and expression of the fas ligand, a novel member of the tumor necrosis factor familyCell, 1993